ORKA-002

DRUG3 trials

Sponsors

Oruka Therapeutics, Inc.

Conditions

Healthy VolunteersHidradenitis Suppurativa (HS)Plaque Psoriasis

Phase 1

ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

Active, not recruitingNCT06944379

Oruka Therapeutics, Inc.Healthy Volunteers

Start: 2025-05-19End: 2027-01-31Target: 24Updated: 2025-09-26

Phase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

RecruitingNCT07474792

Oruka Therapeutics, Inc.Plaque Psoriasis

Start: 2026-03-19End: 2029-04-01Target: 160Updated: 2026-08-10

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

RecruitingNCT07783542

Oruka Therapeutics, Inc.Hidradenitis Suppurativa (HS)

Start: 2026-08-20End: 2029-09-01Target: 200Updated: 2026-08-31